Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone

Bioorganic & Medicinal Chemistry
2020.0

Abstract

1-Phenyl-3-methyl-5-pyrazolone is a reagent, known as PMP, used to derivatize monosaccharides for the study of polysaccharides composition and structure, and for the dosage of carbohydrates in complex media. The same molecule is also known as edaravone, a drug approved for the treatment of stroke and amyotrophic lateral sclerosis. It is also a reactive molecule susceptible to form stable adducts with aromatic aldehydes, such as formylpterin and vanillin. In addition, the molecule serves as a scaffold to design of edaravone analogs and drug conjugates, with various pharmacological properties (antioxidant, anticancer, antiviral). We have analyzed the multiple usages of PMP/edaravone to highlight the reactivity of the molecule and its wide range of applications. This phenyl-pyrazolone compound, considered by many as a biochemical reagent and by other as a clinically useful drug, has not yet revealed the full extent of its capacities and benefits.

Knowledge Graph

Similar Paper

Chemical reactivity and uses of 1-phenyl-3-methyl-5-pyrazolone (PMP), also known as edaravone
Bioorganic & Medicinal Chemistry 2020.0
Hydroxyl radical scavenging by edaravone derivatives: Efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5-pyrazolone with an intramolecular base
Bioorganic & Medicinal Chemistry Letters 2006.0
A theoretical investigation on DPPH radical-Scavenging mechanism of edaravone
Bioorganic & Medicinal Chemistry Letters 2003.0
A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox
Bioorganic & Medicinal Chemistry Letters 2014.0
Diversification of edaravone via palladium-catalyzed hydrazine cross-coupling: Applications against protein misfolding and oligomerization of beta-amyloid
Bioorganic & Medicinal Chemistry Letters 2016.0
Edaravone containing isoindoline nitroxides for the potential treatment of cardiovascular ischaemia
MedChemComm 2011.0
Edaravone Derivatives Containing NO-Donor Functions
Journal of Medicinal Chemistry 2009.0
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs
Bioorganic & Medicinal Chemistry 2012.0
Synthesis, molecular properties prediction and anticancer, antioxidant evaluation of new edaravone derivatives
Bioorganic & Medicinal Chemistry Letters 2016.0
Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect
European Journal of Medicinal Chemistry 2020.0